Durvalumab (MEDI 4736) is a humanized monoclonal antibody targeting PD-L1. It can block the interaction of PD-L1 with PD-1 and CD80, with IC50 values of 0.1 and 0.04 nM, respectively. Durvalumab is often used in combination with platinum-based compounds for the treatment of non-small cell lung cancer and advanced hepatocellular carcinoma cells.

PD-1/PD-L1:0.1 nM, PD-L1/CD80:0.04 nM

In a mouse xenograft model of human melanoma ( A375 ) and pancreatic ( HPAC ) tumor cell lines, Durvalumab inhibits tumor growth through a T cell-mediated mechanism. Compared with the isotype-matched control antibody Durvalumab, both HPAC and A375 xenografts significantly inhibited tumor growth ( 5-0.01 mg / kg for NOD / SCID mice with HPAC tumors ; 5-0.1mg / kg for NOD / SCID mice with A375 tumor ; intraperitoneal administration ; twice a week ; for 3 weeks ), 74 % HPAC cell growth inhibition and 77 % A375 cell growth inhibition were achieved. However, when administered in the absence of T cells, Durvalumab had no effect on the growth of A375 tumor xenografts. [ 2 ]

Human

Immobilized Human PD-L1 Protein (His) (TMPY-04343) at 1 μg/mL (100 μL/well) can bind Durvalumab. The EC50 is 1.210 ng/mL.

Monoclonal

Unconjugated